

**Table 2 Disease Progressions, Treatment and Outcome**

<b>Variables</b>	<b>DM Group (n, 60)</b>	<b>Non-DM Group (n, 89)</b>	<b>P value</b>
<b>Disease Progressions, n (%)</b>	4 (7%)	20 (22%)	0.011
<b>Time from the onset of IMHB (days)</b>	12.0±1.4	6.4±1.3	<0.001
<b>Increased pleural effusion, n (%)</b>	3 (5%)	1 (2%)	0.303
<b>Hematoma thickening (thickness ≥10 mm), n (%)</b>	0 (0%)	1 (1%)	1.000
<b>Development of ULPs</b>	0 (0%)	7 (7%)	0.042
<b>Aortic pseudoaneurysm, n (%)</b>	0 (0%)	1 (2%)	1.000
<b>Aortic dissection, n (%)</b>	1 (2%)	2 (2%)	1.000
<b>Signs of aortic rupture, n (%)</b>	0 (0%)	8 (9%)	0.022
<b>TEVAR during acute phase, n (%)</b>	1 (2%)	11 (12%)	0.028
<b>Died after TEVAR, n</b>	0	2	1.000
<b>Partial/Complete Left subclavian artery coverage, n</b>	0	10	0.006
<b>Arch Reconstructive methods**</b>	0	1	1.000
<b>Fenestration, n</b>	0	1	1.000
<b>Aorta-related mortality during acute phase, n (%)</b>	0 (0%)	8 (9%)	0.042
<b>Aortic rupture, n</b>	0	4	0.149
<b>Ascending aortic pseudoaneurysm, n</b>	0	2	0.516
<b>Retrograde type A aortic dissection, n</b>	0	2	0.516
<b>Mortality after TEVAR, n (%)</b>	0 (0%)	2 (18%)	-
<b>Late Follow-up, n</b>	60	81	-
<b>Aorta-related mortality, n (%)</b>	1 (2%)	9 (11%)	0.043
<b>Non-aorta-related mortality, n (%)</b>	3 (6%)	3 (4%)	1.000
<b>Aortic remodeling of hematoma</b>			
<b>Stable of hematoma</b>	2 (3%)	3 (4%)	1.000
<b>Resolution of hematoma</b>	55 (92%)	60 (74%)	0.011
<b>Worsening of hematoma</b>	3 (5%)	18 (22%)	0.004
<b>Increased pleural effusion</b>	0 (0%)	0 (0%)	-
<b>Hematoma thickening</b>	1 (2%)	2 (2%)	0.240
<b>Development to aneurysm</b>	0 (0%)	2 (2%)	0.072
<b>Development of aortic dissection</b>	1 (2%)	2 (2%)	0.240
<b>Development of ULPs</b>	1 (2%)	4 (5%)	0.138
<b>Signs of aortic rupture</b>	0 (0%)	8 (10%)	0.003
<b>Reinterventions</b>			
<b>Surgical intervention or TEVAR</b>	1 (2%)	9 (11%)	0.043
<b>All-cause mortality, n (%)</b>	4 (7%)	20 (22%)	0.011

TEVAR, thoracic endovascular aortic repair; IMHB, type B intramural hematoma; ULP: Ulcer-like projection

\*Zenith TX2 (Cook, Inc, Bloomington, Ind); Valiant (Medtronic, Inc, Minneapolis, Minn); Ankura (Lifetechmed, Inc, Shenzhen, China).

\*\*Fenestration, in situ laser fenestration technology; Debranching, sequential debranching procedure; Chimney, chimney technique.

